Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,032 total articles
BioMarin (BMRN) is a Strong Buy on a concrete catalyst set: expanding demand for VOXZOGO in skeletal dysplasia and a value-accretive acquisition of Amicus. The balance sheet, free cash flow and a modest valuation frame a favorable risk/reward. Trade plan: enter $54.60, target $68.00, stop $49.00, horizon mid term (45 trading days).
Acme United (ACU) has climbed off its 2025 lows but remains attractively valued relative to its free cash flow, EV/EBITDA and low leverage. The recent My Medic acquisition and consistently paid quarterly dividends create a lower-risk entry for a position trade. We lay out an actionable entry, stop and target with time-based rationale.
Super Micro's Q3 results and forward guidance point to a material margin recovery driven by AI GPU server demand. The stock has rallied hard, but fundamentals plus technical momentum support a defined long swing trade: entry $34.25, stop $28.00, target $46.00 over roughly 45 trading days.
Salesforce (CRM) has been punished with the broader software sell-off, but fundamentals and AI optionality argue against a terminal 'SaaSpocalypse.' With $14.4B in free cash flow, a conservative capital structure and trading well below last year's highs, CRM offers a risk-reward edge. This is a trade: enter $183.00, stop $165.00, target $240.00 ove…
Lithium Americas (LAC) looks poised to re-rate as U.S. policy and tightening supply converge on domestic lithium projects. With a market cap near $2.07B, a strong cash buffer on a per-share basis, and constructive technicals, this trade targets a move back toward last year's highs while protecting capital with a clear stop. Catalysts include faster…
Occidental's asset mix, $4.1B of free cash flow and an EV/EBITDA near 7 create a constructive valuation setup if oil prices stay elevated. This trade idea targets a move back toward the 52-week high with defined entry, stop and target levels and a 180 trading-day horizon, while acknowledging macro and company-specific risks.
Lumentum (LITE) trades near $908.88 on a market cap of roughly $64.9B and valuation multiples (P/E ~304, P/S ~32) that assume flawless scaling. Recent headlines and supply/backlog anecdotes point to constrained manufacturing and stretched working capital - an environment that can produce sharp mean reversion. This is a tactical short idea: enter ne…
Nokia’s strategic shift toward higher-margin infrastructure and cloud-native software, combined with strong demand for optical networking to support 5G and AI-driven data growth, provides a clear catalyst. This trade idea lays out a mid-term swing trade that captures momentum while protecting capital with a defined stop.
Diageo (DEO) has been sold down on near-term top-line weakness and industry consolidation stories, but the company's scale, cash generation and valuation create an asymmetric risk-reward. This trade idea outlines a disciplined long with an entry at $84.00, a $75.00 stop and a $100.00 target on a 45-trading-day horizon, driven by improving sentiment…
Berkshire Hathaway is a once-in-a-generation conglomerate with a $1.01T market cap, a deep cash war chest and free cash flow generation that supports opportunistic buying. Recent weakness and a below-peak valuation make incremental buys attractive. This trade idea lays out an entry near $700,000, a conservative stop at the 52-week low, and a target…
Amazon is deploying two capital-intensive engines - AI infrastructure and an open logistics product - that together can re-price a multi-trillion dollar addressable market. The stock trades near $275 with a $2.98T market cap; we argue a disciplined long here captures upside as AWS AI monetization and Amazon Supply Chain Services scale. Risk is real…
Venture Global (VG) is being repriced higher as a structural LNG supply shock and fresh offtake/financing wins make the company a near-term beneficiary. We upgrade the rating to a tactical Buy and propose a clear trade: enter at $12.00, stop at $9.50, target $22.00 over a 180-trading-day horizon, with strict position sizing given leverage and negat…
Peoples Bancorp of North Carolina (PEBK) is trading at roughly 1.3x book and a mid-teens ROE after a steady run of dividends and positive free cash flow. The stock offers a reasonable entry for a patient, defined-risk long trade over the next 180 trading days, with upside from multiple expansion and modest earnings growth while downside is capped b…
Madison Square Garden Sports (MSGS) shows constructive price action backed by rising short interest, a tight float and improving technicals. We lay out an entry at $338.16 with a $355 target and a $322 stop, sized for a mid-term trade (45 trading days) that aims to capture near-term upside while respecting seasonality and valuation risks.
AMD just showed up to the AI party in force. Strong Q1 2026 results and bullish commentary on EPYC CPUs plus Instinct GPUs produced a 16%-20% post-earnings lift. This trade outlines a disciplined long idea: enter on consolidation, use a tight stop to limit downside, and target a multi-stage re-rating if execution continues and AI spending holds.
Sysco's announced acquisition of Jetro Restaurant Depot creates a combined company with roughly $100B in revenue, immediate margin accretion, and $250M of targeted synergies. With a market cap near $35.4B, an EV/EBITDA of 12 and free cash flow of $1.82B, the risk/reward favors a long position for patient investors who accept integration risk and hi…
Harley-Davidson is a beaten-down iconic brand trading near $2.8B market cap with meaningful cash flow and an active turnaround plan. We upgrade to a bullish stance and recommend a mid-term long trade: entry $25.61, target $31.25, stop $22.00. The risk/reward is attractive given EV/EBITDA ~3.9, free cash flow of $415M, and technical momentum; execut…
Vornado trades at bargain multiples (P/E ~6.8, P/B ~0.93) but those headline metrics obscure an unfinished operating recovery in Manhattan office fundamentals and meaningful leverage. Recent asset buys and a $500M bond issue extend maturities but don't guarantee stabilized NOI. I recommend a mid-term short: enter at the current price, stop at $33.5…
Berkshire Hathaway under Greg Abel is not a broken investment thesis — it’s a capital allocator with a $397B+ war chest, low leverage and a diversified cash engine. Technicals show near-term weakness, creating a disciplined entry for a long-term trade. This plan targets a recovery to new highs while protecting capital with a conservative stop-loss.
Krystal Biotech (KRYS) looks attractive after a market-interpreted Q1 beat and continued commercial traction for VYJUVEK. Strong cash, robust free cash flow, and multiple near-term clinical readouts in 2026-2027 create a clear catalyst path. This trade idea recommends a long at a defined entry with stop and target aligned to key binary events and v…
Nexxen looks like a small-cap mispriced for steady execution. The trade outlined below is an actionable, defined-risk long aiming to capture a structural re-rating driven by product traction, margin recovery, and potential corporate actions.
New Jersey Resources (NJR) reported another quarter of better-than-expected results and sits near its 52-week high on constructive fundamentals: EPS of $3.24, a P/E near 16.7, market cap ~$5.64B and a 3.34% dividend yield. Regulatory rate filings and continued stable distribution operations underpin our bullish view. We lay out a long trade with en…
Amprius (AMPX) is trading near its 52-week high after a sustained rally driven by production progress, NDAA-related defense access, and strong trading flow. The company is priced like a growth winner — market cap ~$2.93B, P/S ~40 — so the trade is a bet that near-term execution (ramp, orders, yields) keeps accelerating. I outline a mid-term swing l…
Luckin is a scale-first, tech-driven coffee chain with rapid unit growth and recovering customer metrics. Near-term headline noise and a controlling-shareholder deal create debate, but revenue growth and a sub-$10B market cap argue for a long-biased trade with a disciplined stop.
Alkermes ($ALKS) is a cash-flowing CNS company that just picked up a sleep medicine asset (Lumryz) via the Avadel deal. The stock is trading near its 52-week high but still offers asymmetric upside to $42.50 if Lumryz momentum and the core CNS portfolio line up. This trade plan targets a mid-term swing (45 trading days) with a disciplined stop at $…
